13:55:47 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-20 Bokslutskommuniké 2024
2024-11-21 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-24 Ordinarie utdelning VIVE 0.00 SEK
2024-05-23 Kvartalsrapport 2024-Q1
2024-05-23 Årsstämma 2024
2024-02-22 Bokslutskommuniké 2023
2023-11-16 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-26 Ordinarie utdelning VIVE 0.00 SEK
2023-05-25 Kvartalsrapport 2023-Q1
2023-05-25 Årsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-27 Ordinarie utdelning VIVE 0.00 SEK
2022-05-25 Årsstämma 2022
2022-05-25 Kvartalsrapport 2022-Q1
2022-02-23 Bokslutskommuniké 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-28 Ordinarie utdelning VIVE 0.00 SEK
2021-05-25 Kvartalsrapport 2021-Q1
2020-09-10 Ordinarie utdelning VIVE 0.00 SEK
2020-09-09 Årsstämma 2021
2020-06-18 Bokslutskommuniké 2020
2020-05-14 Extra Bolagsstämma 2020
2020-03-27 Kvartalsrapport 2020-Q3
2019-12-30 Kvartalsrapport 2020-Q2
2019-11-06 Extra Bolagsstämma 2019
2019-09-27 Ordinarie utdelning VIVE 0.00 SEK
2019-09-26 Årsstämma 2020
2019-09-26 Kvartalsrapport 2020-Q1
2019-07-12 Bokslutskommuniké 2019
2019-03-01 Kvartalsrapport 2019-Q3
2018-11-30 Kvartalsrapport 2019-Q2
2018-09-25 Årsstämma 2019
2018-09-05 Ordinarie utdelning VIVE 0.00 SEK
2018-08-31 Kvartalsrapport 2019-Q1
2018-06-08 Bokslutskommuniké 2018
2018-03-02 Kvartalsrapport 2018-Q3
2017-12-01 Kvartalsrapport 2018-Q2
2017-09-26 Ordinarie utdelning VIVE 0.00 SEK
2017-09-25 Årsstämma 2018
2017-09-01 Kvartalsrapport 2018-Q1
2017-06-08 Bokslutskommuniké 2017
2017-03-03 Kvartalsrapport 2017-Q3
2016-12-02 Kvartalsrapport 2017-Q2
2016-11-21 Extra Bolagsstämma 2016
2016-09-27 Ordinarie utdelning VIVE 0.00 SEK
2016-09-26 Årsstämma 2017
2016-09-02 Kvartalsrapport 2017-Q1
2016-06-03 Bokslutskommuniké 2016
2016-03-03 Kvartalsrapport 2016-Q3
2015-12-03 Kvartalsrapport 2016-Q2
2015-09-29 Ordinarie utdelning VIVE 0.00 SEK
2015-09-28 Årsstämma 2016
2015-09-03 Kvartalsrapport 2016-Q1
2015-06-04 Bokslutskommuniké 2015
2015-03-05 Kvartalsrapport 2015-Q3
2014-12-04 Kvartalsrapport 2015-Q2
2014-09-30 Ordinarie utdelning VIVE 0.00 SEK
2014-09-29 Årsstämma 2015
2014-09-05 Kvartalsrapport 2015-Q1
2014-06-05 Bokslutskommuniké 2014
2014-03-06 Kvartalsrapport 2014-Q3
2013-12-05 Kvartalsrapport 2014-Q2
2013-10-01 Ordinarie utdelning VIVE 0.00 SEK
2013-09-06 Kvartalsrapport 2014-Q1
2013-06-07 Bokslutskommuniké 2013
2013-03-13 15-7 2013
2013-03-01 Kvartalsrapport 2012-Q3
2012-12-06 Kvartalsrapport 2012-Q2
2012-09-25 Ordinarie utdelning VIVE 0.00 SEK
2012-09-24 Årsstämma 2012
2012-09-06 Kvartalsrapport 2012-Q1
2012-06-14 Bokslutskommuniké 2011
2012-03-08 Kvartalsrapport 2011-Q3
2011-12-08 Kvartalsrapport 2011-Q2
2011-10-03 Ordinarie utdelning VIVE 0.00 SEK
2011-09-30 Årsstämma 2011
2011-09-08 Kvartalsrapport 2011-Q1
2011-06-10 Bokslutskommuniké 2010
2010-12-09 Kvartalsrapport 2010-Q2
2010-09-24 Årsstämma 2010
2010-09-09 Kvartalsrapport 2010-Q1
2009-12-10 Kvartalsrapport 2009-Q3

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Vivesto är ett forskningsbolag. Bolaget är specialiserat inom forskning och utveckling av läkemedel för svåra sjukdomar inom onkologi. Tekniken baseras på bolagets tekniska plattform där forskning sker utifrån nanoteknik. Idag innehas verksamhet främst inom Norden och Nordamerika. Bolaget grundades under 1999 och har idag sitt huvudkontor i Uppsala.
2022-07-21 15:30:00

Solna, Sweden, 21 July 2022 – Vivesto AB (“Vivesto” or the “Company”), an oncology-focused specialty pharmaceutical company, hereby announces that the Board of Directors of the Company today has appointed Christer Nordstedt as acting CEO of the Company.

Christer assumes the position as acting CEO on 21 July 2022 and will hold the position until the recruitment of a permanent CEO is completed.

Peter Zonabend, Chairman of the Board of Vivesto, says: “We are very pleased to appoint Christer Nordstedt as acting CEO. Christer has a proven track record within R&D and his leadership ensures that we will achieve our goals. With his long and very relevant experience in R&D, Christer will be able to continue the strategic direction of Vivesto to become a strong oncology company through own development and future partnerships.”

Christer Nordstedt is a Doctor of Medicine and has a PhD in Pharmacology and Biochemistry from the Karolinska Institute in Sweden and did his postdoctoral training with the Nobel laureate Paul Greengard at Rockefeller University in New York. Christer has many years of experience, including leading a large number of projects in the pharmaceutical industry from the earliest discovery all the way through clinical development, and has held positions such as Global Head of Specialty Research and Clinical Development and Senior Vice President Global Head of Clinical Development at Teva Pharmaceuticals, Head of R&D at Orion Cooperation as well as Senior Vice President at Hoffman-LaRoche in Basel and at Eli Lilly in Indianapolis. Currently, Christer is Chairman of the Board of WntResearch AB and engaged as a consultant at BioArctic AB. Christer does not own any shares or share-related instruments in Vivesto.

For More Information:

Vivesto AB

Peter Zonabend, Chairman of the Board of Vivesto

Phone: +46 18-50 54 40

E-mail: IR@vivesto.com

Consilium Strategic Communications (For Vivesto)

Jonathan Birt, Ashley Tapp

Phone: +44 (0) 20 3709 5700

E-mail: vivesto@consilium-comms.com

About Vivesto AB

Vivesto is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Vivesto has proprietary drug delivery technology designed to improve solubility, efficacy and safety. Vivesto’s shares are traded on Nasdaq Stockholm (VIVE). To find out more about Vivesto please visit www.vivesto.com.